tawandamusarurwa
Roselyne Sachiti in BRISBANE AUSTRALIA
IAS 2023, the 12th IAS Conference on HIV Science, which kicks off here today will feature an array of studies that represent important advances in HIV prevention, treatment and cure research.
Highlights include results from a study showing that cisgender women in seven African countries prefer long-acting injectable to daily oral PrEP for HIV prevention, WHO analyses examining how mpox and Covid-19 have affected people living with HIV, and three studies that offer new insights in the quest for an HIV cure.
“This is an incredibly exciting time in HIV research, and the studies at IAS 2023 reflect that,” said Sharon Lewin, IAS president, IAS 2023 international chair and director of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne in Australia.
“The science presented at this conference will guide rollout of game-changing prevention tools like long-acting PrEP, shed light on how to reduce the impact of mpox and Covid-19 on people living with HIV, and identify new approaches to achieve an HIV Cure.”
IAS 2023 is taking place in Brisbane, Australia, as well as virtually from July 23 to 26. The conference brings together thousands of scientists, policy makers and advocates to examine the latest advances in HIV research and forge a more equitable and innovative HIV response.
Online Reporter